ConMed reported 1Q19 orthopedic revenue of USD $113.4MM, +4.2% vs. 1Q18.
- Increased 2019 guidance by .25%, bringing the range to 5.25% to 6.25%
- Sixth consecutive quarter of orthopedic revenue growth
- Orthopedic revenue driven by new products like the cordless MicroFree System
- Released a hip system with additional components slated for launch in 1H19
ConMed’s segment sales and growth on an as-reported basis are as follows ($MM).
1Q19 | 1Q18 | $ Chg | % Chg | |
Sports Medicine | $113.4 | $108.9 | $4.6 | 4.2% |
ORTHOWORLD estimates ConMed’s orthopedic revenue by geographic region as follows ($MM).
Geographic Region | 1Q19 | 1Q18 | $ Chg | % Chg |
U.S. | $43.8 | $41.3 | $2.5 | 6.1% |
Ex-U.S. | $69.6 | $67.6 | $2.0 | 3.0% |
EMEA | $28.7 | $28.0 | $0.7 | 2.5% |
Asia Pacific | $24.1 | $23.5 | $0.5 | 2.3% |
Rest of World | $16.9 | $16.1 | $0.8 | 4.8% |
Total | $113.4 | $108.9 | $4.6 | 4.2% |
Net earnings are as follows, inclusive of all ConMed revenue.
1Q19 | Amount ($MM) | % of Sales |
Sales | $218.4 | |
Cost of Sales | -$96.9 | 44.4% |
Selling and Admin | -$99.2 | 45.4% |
R&D | -$10.6 | 4.8% |
Other | -$10.6 | 4.9% |
Net Earnings | $1.0 | 0.5% |
Sources: ConMed; ORTHOWORLD estimates.
Mike Evers is ORTHOWORLD’s Market Analyst. He can be reached by email.
ConMed reported 1Q19 orthopedic revenue of USD $113.4MM, +4.2% vs. 1Q18.
Increased 2019 guidance by .25%, bringing the range to 5.25% to 6.25%
Sixth consecutive quarter of orthopedic revenue growth
Orthopedic revenue driven by new products like the cordless MicroFree System
Released a hip system with additional components slated...
ConMed reported 1Q19 orthopedic revenue of USD $113.4MM, +4.2% vs. 1Q18.
- Increased 2019 guidance by .25%, bringing the range to 5.25% to 6.25%
- Sixth consecutive quarter of orthopedic revenue growth
- Orthopedic revenue driven by new products like the cordless MicroFree System
- Released a hip system with additional components slated for launch in 1H19
ConMed’s segment sales and growth on an as-reported basis are as follows ($MM).
1Q19 | 1Q18 | $ Chg | % Chg | |
Sports Medicine | $113.4 | $108.9 | $4.6 | 4.2% |
ORTHOWORLD estimates ConMed’s orthopedic revenue by geographic region as follows ($MM).
Geographic Region | 1Q19 | 1Q18 | $ Chg | % Chg |
U.S. | $43.8 | $41.3 | $2.5 | 6.1% |
Ex-U.S. | $69.6 | $67.6 | $2.0 | 3.0% |
EMEA | $28.7 | $28.0 | $0.7 | 2.5% |
Asia Pacific | $24.1 | $23.5 | $0.5 | 2.3% |
Rest of World | $16.9 | $16.1 | $0.8 | 4.8% |
Total | $113.4 | $108.9 | $4.6 | 4.2% |
Net earnings are as follows, inclusive of all ConMed revenue.
1Q19 | Amount ($MM) | % of Sales |
Sales | $218.4 | |
Cost of Sales | -$96.9 | 44.4% |
Selling and Admin | -$99.2 | 45.4% |
R&D | -$10.6 | 4.8% |
Other | -$10.6 | 4.9% |
Net Earnings | $1.0 | 0.5% |
Sources: ConMed; ORTHOWORLD estimates.
Mike Evers is ORTHOWORLD’s Market Analyst. He can be reached by email.
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
ME
Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.